NASDAQ:SLXP - Salix Pharmaceuticals Stock Price, Price Target & More

$172.81 0.00 (0.00 %)

(As of 04/25/2018 03:03 AM ET)

Previous Close$172.81

Today's RangeN/A

52-Week Range$86.00 - $172.98

VolumeN/A

Average Volume4.96 million shs

Market Capitalization$10.94 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.94

About Salix Pharmaceuticals (NASDAQ:SLXP)

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.

Receive SLXP News and Ratings via Email

Sign-up to receive the latest news and ratings for SLXP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A

Sub-IndustryPharmaceuticals

SectorN/A

SymbolNASDAQ:SLXP

CUSIP79543510

Webwww.salix.com

Phone+1-919-8621000

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / CashN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net Margins-2,134.34%

Return on Equity-305.24%

Return on Assets-25.83%

Miscellaneous

EmployeesN/A

Outstanding Shares64,250,000

How to Become a New Pot Stock Millionaire

Salix Pharmaceuticals (NASDAQ:SLXP) Frequently Asked Questions

What is Salix Pharmaceuticals' stock symbol?

Salix Pharmaceuticals trades on the NASDAQ under the ticker symbol "SLXP."

How were Salix Pharmaceuticals' earnings last quarter?

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced its earnings results on Monday, March, 2nd. The specialty pharmaceutical company reported ($2.61) earnings per share for the quarter, missing the consensus estimate of ($0.29) by $2.32. The specialty pharmaceutical company earned $13 million during the quarter, compared to analysts' expectations of $187.97 million. Salix Pharmaceuticals had a negative net margin of 2,134.34% and a negative return on equity of 305.24%. During the same quarter last year, the business posted $1.06 earnings per share. View Salix Pharmaceuticals' Earnings History.

Has Salix Pharmaceuticals been receiving favorable news coverage?

News articles about SLXP stock have been trending positive on Wednesday, Accern Sentiment reports. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Salix Pharmaceuticals earned a daily sentiment score of 0.35 on Accern's scale. They also gave news stories about the specialty pharmaceutical company an impact score of 48.19 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Salix Pharmaceuticals?

Shares of SLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Salix Pharmaceuticals' stock price today?

One share of SLXP stock can currently be purchased for approximately $172.81.

How big of a company is Salix Pharmaceuticals?

Salix Pharmaceuticals has a market capitalization of $10.94 billion.

How can I contact Salix Pharmaceuticals?

Salix Pharmaceuticals' mailing address is 8510 Colonnade Center Dr, RALEIGH, NC 27615-3050, United States. The specialty pharmaceutical company can be reached via phone at +1-919-8621000.

MarketBeat Community Rating for Salix Pharmaceuticals (SLXP)

Community Ranking:		2.7 out of 5 ( )
Outperform Votes:		331 (Vote Outperform)
Underperform Votes:		290 (Vote Underperform)
Total Votes:		621

MarketBeat's community ratings are surveys of what our community members think about Salix Pharmaceuticals and other stocks. Vote "Outperform" if you believe SLXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLXP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Salix Pharmaceuticals (NASDAQ:SLXP) Analyst Ratings History

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details

(Data available from 4/25/2016 forward)

Salix Pharmaceuticals (NASDAQ:SLXP) Earnings History and Estimates Chart

Earnings by Quarter for Salix Pharmaceuticals (NASDAQ:SLXP)

Salix Pharmaceuticals (NASDAQ SLXP) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
3/2/2015	Q414	($0.29)	($2.61)	$187.97 million	$13.00 million	View	N/A
11/6/2014	Q314	$1.56	$1.53	$394.00 million	$354.70 million	View	N/A
8/7/2014	Q214	$1.69	$1.59	$397.06 million	$382.00 million	View	Listen
5/8/2014	Q114	$0.91	$1.05	$372.91 million	$384.00 million	View	Listen
2/27/2014	Q413	$0.93	$1.06	$247.29 million	$257.60 million	View	Listen
11/7/2013	Q313	$0.86	$0.89	$239.70 million	$238.20 million	View	N/A
8/8/2013	Q2 2013	$0.81	$0.87	$226.34 million	$235.40 million	View	Listen
5/9/2013	Q1 2013	$0.67	$0.63	$205.94 million	$202.60 million	View	Listen
2/28/2013	Q4 2012	$0.78	$0.81	$199.41 million	$198.17 million	View	N/A
11/7/2012	Q312	$0.69	$0.95	$187.23 million	$185.13 million	View	N/A
8/8/2012		$0.54	$0.79			View	N/A
5/7/2012		$0.56	$0.67			View	N/A
2/27/2012	Q4 2011	$0.97	$1.18			View	N/A
11/8/2011		$0.60	$0.77			View	N/A
8/8/2011		$0.44	$0.32			View	N/A
5/5/2011		$0.17	$0.34			View	N/A
2/28/2011		$0.49	$0.66			View	N/A
11/8/2010	Q3 2010	($0.15)	($0.05)			View	N/A
8/9/2010	Q2 2010	$0.10	$0.13			View	N/A
5/10/2010	Q1 2010	($0.51)	($0.45)			View	N/A
3/9/2010	Q4 2009	($0.14)	($0.13)			View	N/A
11/9/2009	Q3 2009	($0.29)	($0.15)			View	N/A
8/10/2009	Q2 2009	($0.34)	($0.32)			View	N/A
5/5/2009	Q1 2009	($0.37)	($0.29)			View	N/A
3/10/2009	Q4 2008	($0.11)	($0.22)			View	N/A
11/5/2008	Q3 2008	($0.31)	($0.11)			View	N/A
8/4/2008	Q2 2008	($0.37)	($0.15)			View	N/A
5/6/2008	Q1 2008	($0.46)	($0.50)			View	N/A
3/3/2008	Q4 2007	$0.32	$0.32			View	N/A

(Earnings results data provided by Zacks Investment Research)

Salix Pharmaceuticals (NASDAQ:SLXP) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Salix Pharmaceuticals (NASDAQ SLXP) Insider Trading and Institutional Ownership History

Insider Trading History for Salix Pharmaceuticals (NASDAQ:SLXP)

Salix Pharmaceuticals (NASDAQ SLXP) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/6/2015	Timothy J Creech	Insider	Sell	4,600	$157.67	$725,282.00
3/6/2015	William P Forbes	EVP	Sell	20,000	$157.96	$3,159,200.00
11/12/2014	William P Forbes	EVP	Sell	11,079	$95.05	$1,053,058.95
6/26/2014	Carolyn J Logan	CEO	Sell	53,057	$123.38	$6,546,172.66
4/22/2014	Alonzo Thomas D	Director	Sell	11,530	$110.89	$1,278,561.70	79,179
1/10/2014	Alonzo Thomas D	Director	Sell	12,050	$91.83	$1,106,551.50	97,974
1/9/2014	Adam Derbyshire	CFO	Sell	30,001	$91.48	$2,744,491.48	179,395
1/8/2014	William Forbes	EVP	Sell	8,000	$90.06	$720,480.00	81,573
1/7/2014	Rick Scruggs	EVP	Sell	8,463	$88.31	$747,367.53	53,714
1/7/2014	William Keane	Director	Sell	22,500	$88.31	$1,986,975.00	35,240
7/24/2013	William P Forbes	EVP	Sell	12,000	$70.93	$851,160.00
4/10/2013	William P Forbes	EVP	Sell	8,673	$49.37	$428,186.01
12/26/2012	Adam C Derbyshire	CFO	Sell	60,000	$41.44	$2,486,400.00
11/13/2012	Mark A Sirgo	Director	Sell	3,450	$40.53	$139,828.50

(Data available from 1/1/2013 forward)

Salix Pharmaceuticals (NASDAQ SLXP) News Headlines

Source:

Date	Headline
	Salix Provides Update on FDA Submission for PLENVU®* www.prnewswire.com - February 9 at 9:28 AM
	Financial Analysis: Salix Pharmaceuticals (SLXP) vs. Advanced Accelerator Application (AAAP) www.americanbankingnews.com - January 26 at 11:08 PM
	Reviewing Salix Pharmaceuticals (SLXP) and Advanced Accelerator Application (AAAP) www.americanbankingnews.com - January 7 at 11:26 PM
	Reviewing Salix Pharmaceuticals (SLXP) & Check Cap (CHEK) www.americanbankingnews.com - December 19 at 11:24 AM
	Salix Pharmaceuticals (SLXP) versus Its Competitors Head-To-Head Contrast www.americanbankingnews.com - December 3 at 4:14 PM
	Critical Analysis: Eagle Pharmaceuticals (EGRX) and Salix Pharmaceuticals (SLXP) www.americanbankingnews.com - December 1 at 5:12 PM
	Financial Analysis: Salix Pharmaceuticals (SLXP) and Aimmune Therapeutics (AIMT) www.americanbankingnews.com - November 29 at 11:30 PM
	Salix Pharmaceuticals (SLXP) versus Its Rivals Critical Analysis www.americanbankingnews.com - November 29 at 1:14 AM
	Analyzing Salix Pharmaceuticals (SLXP) and The Competition www.americanbankingnews.com - November 24 at 7:20 PM
	Financial Comparison: Salix Pharmaceuticals (SLXP) & Its Competitors www.americanbankingnews.com - November 22 at 9:42 AM
	Salix Pharmaceuticals (SLXP) and Its Competitors Critical Analysis www.americanbankingnews.com - November 20 at 5:16 AM
	Analyzing Salix Pharmaceuticals (SLXP) and Its Competitors www.americanbankingnews.com - November 19 at 9:26 PM
	Critical Review: Salix Pharmaceuticals (SLXP) vs. Its Competitors www.americanbankingnews.com - November 19 at 7:12 AM
	Salix Pharmaceuticals (SLXP) vs. Its Rivals Head to Head Survey www.americanbankingnews.com - November 18 at 9:08 PM
	Salix Pharmaceuticals (SLXP) versus Its Rivals Financial Survey www.americanbankingnews.com - November 13 at 7:30 PM
	Critical Comparison: Salix Pharmaceuticals (SLXP) vs. Its Competitors www.americanbankingnews.com - November 5 at 7:16 PM
	Financial Survey: Salix Pharmaceuticals (SLXP) & The Competition www.americanbankingnews.com - November 4 at 7:29 PM
	Valeant Pharmaceuticals Intl Inc (VRX) To Retain Salix Pharmaceuticals, Ltd. (SLXP) After Negotiations With Takeda Pharmaceutical Co Ltd (ADR) (TKPYY) Collapse finance.yahoo.com - October 6 at 11:03 AM
	Contrasting Supernus Pharmaceuticals (SUPN) & Salix Pharmaceuticals (SLXP) www.americanbankingnews.com - September 28 at 10:48 AM
	Critical Survey: Salix Pharmaceuticals (SLXP) vs. Assembly Biosciences (ASMB) www.americanbankingnews.com - September 23 at 10:28 PM
	Mallinckrodt PLC (MNK) and Salix Pharmaceuticals (SLXP) Critical Review www.americanbankingnews.com - September 11 at 12:08 AM
	Salix Pharmaceuticals (SLXP) versus AbbVie (ABBV) Head to Head Survey www.americanbankingnews.com - September 3 at 10:24 PM
	Head to Head Analysis: AbbVie (ABBV) and Salix Pharmaceuticals (SLXP) www.americanbankingnews.com - August 15 at 12:16 PM
	Financial Comparison: Salix Pharmaceuticals (SLXP) versus Novan (NOVN) www.americanbankingnews.com - July 31 at 9:41 AM
	Bill Ackman To Investors: 'Deeply And Profoundly' Sorry For The Valeant Fiasco www.benzinga.com - March 31 at 1:09 AM
	Valeant stock falls 5% after company files 10-K www.marketwatch.com - March 1 at 8:14 PM
	[$$] Allergan Admits to Disclosure Violations During Valeant Bid www.wsj.com - February 9 at 4:24 AM
	Valeant Pharmaceuticals: We Were Wrong, Morgan Stanley Says blogs.barrons.com - December 16 at 3:56 AM
	Why Valeant is Crumbling us.rd.yahoo.com - December 1 at 1:11 AM
	Valeant: First No Salix Sale, Now the SEC Sees Accounting Issues?!?! blogs.barrons.com - November 30 at 8:09 PM
	Uh Oh, Valeant's Hiring. Why That's Very Bad News. blogs.barrons.com - November 30 at 10:42 AM
	Valeant's Asset Sale Clock is Ticking www.bloomberg.com - November 21 at 12:47 PM
	Is Valeant Pharmaceuticals the Turnaround Opportunity of a Lifetime? www.fool.com - November 18 at 7:07 PM
	[$$] New Valeant chief nurses $1.3m paper loss on shares www.ft.com - November 13 at 11:23 AM
	Ackman: Valeant Can Sell Non-Core Assets to Reduce Debt www.thestreet.com - November 10 at 7:29 PM
	Selling Salix Could Be the Most "Valeant" Move Ever www.fool.com - November 9 at 7:34 PM
	Valeant Pharmaceuticals Just Delivered a Trifecta of Bad News in Its Q3 Report www.fool.com - November 9 at 10:15 AM
	Valeant's Possible Fire Sale Looks Worse Than Ever www.bloomberg.com - November 8 at 7:24 PM
	[$$] Valeant shares fall after sales and earnings targets cut www.ft.com - November 8 at 11:22 AM
	Analysts Remain Wary Ahead of Valeant Earnings www.thestreet.com - November 7 at 8:23 PM
	Valeant earnings: Expect an update on plans to sell Salix www.marketwatch.com - November 7 at 8:23 PM
	[$$] Valeant: I love you, you pay my rent www.ft.com - November 2 at 7:51 PM
	Negative Analyst Commentary Pushes Valeant Pharmaceuticals Intl. Inc. Lower by 11% www.fool.com - November 2 at 7:51 PM
	Valeant: A Good Strategic Move? blogs.barrons.com - November 2 at 7:51 PM
	Valeant: Selling Salix a Warning of Trouble to Come? blogs.barrons.com - November 2 at 11:02 AM
	Hold the Valeant Applause www.bloomberg.com - November 2 at 11:02 AM
	Valeant gets new approval for legacy Salix drug www.bizjournals.com - July 20 at 1:50 PM
	Valeant's Drug Approvals May Save the Day www.thestreet.com - July 20 at 12:30 PM
	How Much Is Valeant Pharmaceuticals Really Worth? www.fool.com - June 17 at 2:41 PM
	Details of kickbacks and fraud emerge in Valeant's Salix unit settlement www.bizjournals.com - June 10 at 11:55 AM